Sarah Gutkind1, Laura E Starbird2, Sean M Murphy3, Paul A Teixeira4, Lauren K Gooden5, Tim Matheson6, Daniel J Feaster7, Mamta K Jain8, Carmen L Masson9, David C Perlman10, Carlos Del Rio11, Lisa R Metsch12, Bruce R Schackman13. 1. Department of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: sg3787@cumc.columbia.edu. 2. Columbia University School of Nursing, 560 West 168th St, New York, NY 10032, USA. Electronic address: starbird@nursing.upenn.edu. 3. Department of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: smm2010@med.cornell.edu. 4. Department of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: pault212@gmail.com. 5. Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 W 168th St, New York, NY 10032, USA. Electronic address: lkg2129@columbia.edu. 6. San Francisco Department of Health, 101 Grove St, San Francisco, CA 94102, USA. Electronic address: tim.matheson@sfdph.org. 7. Department of Epidemiology and Public Health, University of Miami School of Medicine, 1120 NW 14th St Miami, FL 33136, USA. Electronic address: DFeaster@biostat.med.miami.edu. 8. Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA. Electronic address: Mamta.Jain@UTSouthwestern.edu. 9. Department of Psychiatry and Behavioral Sciences, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA. Electronic address: Carmen.Masson@ucsf.edu. 10. Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: David.Perlman@mountsinai.org. 11. Department of Global Health, Rollins School of Public Health at Emory University, 1518 Clifton Rd NE, Atlanta, GA 30322, USA. Electronic address: cdelrio@emory.edu. 12. Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 W 168th St, New York, NY 10032, USA. Electronic address: lm2892@columbia.edu. 13. Department of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: brs2006@med.cornell.edu.
Abstract
BACKGROUND: Using data from a randomized trial, we evaluated the cost of HCV care facilitation that supports moving along the continuum of care for HIV/HCV co-infected individuals with substance use disorder. METHODS: Participants were HIV patients residing in the community, initially recruited from eight US hospital sites. They received HCV care facilitation (n = 51) or treatment as usual (n = 62) for up to six months. We used micro-costing methods to evaluate costs from the healthcare sector and patient perspectives in 2017 USD. We conducted sensitivity analyses varying care facilitator caseloads and examined offsetting savings using participant self-reported healthcare utilization. RESULTS: The average site start-up cost was $6320 (site range: $4320-$7000), primarily consisting of training. The mean weekly cost per participant was $20 (site range: $4-$30) for care facilitation visits and contacts, $360 (site range: $130- $700) for supervision and client outreach, and $70 (site range: $20-$180) for overhead. In sensitivity analyses applying a weekly caseload of 10 participants per care facilitator (versus 1-6 observed in the trial), the total mean weekly care facilitation cost from the healthcare sector perspective decreased to $110. Weekly participant time and travel costs averaged $7. There were no significant differences in other healthcare service costs between participants in the intervention and control arms. CONCLUSION: Weekly HCV care facilitation costs were approximately $450 per participant, but approximately $110 at a real-world setting maximum caseload of 10 participants per week. No healthcare cost offsets were identified during the trial period, although future savings might result from successful HCV treatment.
BACKGROUND: Using data from a randomized trial, we evaluated the cost of HCV care facilitation that supports moving along the continuum of care for HIV/HCV co-infected individuals with substance use disorder. METHODS: Participants were HIV patients residing in the community, initially recruited from eight US hospital sites. They received HCV care facilitation (n = 51) or treatment as usual (n = 62) for up to six months. We used micro-costing methods to evaluate costs from the healthcare sector and patient perspectives in 2017 USD. We conducted sensitivity analyses varying care facilitator caseloads and examined offsetting savings using participant self-reported healthcare utilization. RESULTS: The average site start-up cost was $6320 (site range: $4320-$7000), primarily consisting of training. The mean weekly cost per participant was $20 (site range: $4-$30) for care facilitation visits and contacts, $360 (site range: $130- $700) for supervision and client outreach, and $70 (site range: $20-$180) for overhead. In sensitivity analyses applying a weekly caseload of 10 participants per care facilitator (versus 1-6 observed in the trial), the total mean weekly care facilitation cost from the healthcare sector perspective decreased to $110. Weekly participant time and travel costs averaged $7. There were no significant differences in other healthcare service costs between participants in the intervention and control arms. CONCLUSION: Weekly HCV care facilitation costs were approximately $450 per participant, but approximately $110 at a real-world setting maximum caseload of 10 participants per week. No healthcare cost offsets were identified during the trial period, although future savings might result from successful HCV treatment.
Authors: Jason Grebely; Sarah Larney; Amy Peacock; Samantha Colledge; Janni Leung; Matthew Hickman; Peter Vickerman; Sarah Blach; Evan B Cunningham; Kostyantyn Dumchev; Michael Lynskey; Jack Stone; Adam Trickey; Homie Razavi; Richard P Mattick; Michael Farrell; Gregory J Dore; Louisa Degenhardt Journal: Addiction Date: 2018-08-28 Impact factor: 6.526
Authors: Meredith E Clement; Lauren F Collins; Julius M Wilder; Michael Mugavero; Taryn Barker; Susanna Naggie Journal: Infect Dis Clin North Am Date: 2018-06 Impact factor: 5.982
Authors: Aaron M Harris; Mohammed A Khan; Ademola Osinubi; Noele P Nelson; William W Thompson Journal: Am J Prev Med Date: 2021-08-03 Impact factor: 5.043
Authors: Laura J Dunlap; Gary A Zarkin; Stephen Orme; Angelica Meinhofer; Sharon M Kelly; Kevin E O'Grady; Jan Gryczynski; Shannon G Mitchell; Robert P Schwartz Journal: J Subst Abuse Treat Date: 2018-07-31
Authors: Philip R Spradling; Yuna Zhong; Anne C Moorman; Loralee B Rupp; Mei Lu; Stuart C Gordon; Eyasu H Teshale; Mark A Schmidt; Yihe G Daida; Joseph A Boscarino Journal: Hepatol Commun Date: 2020-11-29